Transgenic Zebrafish Model for Stroke and CCM Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current animal models, such as mice, are costly and inefficient for systematically screening drug candidates for treating cerebral cavernous malformations (CCM) and related diseases like stroke, due to high workload and costs, while zebrafish models lack the ability to replicate blood flow-dependent hemorrhagic conditions found in CCM patients.
Innovation Solution
A transgenic zebrafish model lacking endogenous functional proteins required for a functional CCM complex, with an exogenous nucleic acid encoding a functional version of these proteins under endocardium-specific genetic control, which develops vascular lesions in cerebral blood vessels, mimicking human CCM and hemorrhagic stroke conditions, allowing for pharmacological effect measurement of drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mice are used as animal models for CCM and stroke research, then the model can replicate human pathology, but the workload and costs are high making systematic drug screening inefficient
Solution Approach 1:
The patent creates a zebrafish model that copies the essential pathological features of human CCM and stroke (vascular lesions, hemorrhagic conditions) without requiring the complex infrastructure needed for mouse models. This allows high-throughput screening while maintaining pathological relevance through the two-hit mechanism replication and blood flow-dependent lesion development
Solution Approach 2:
Zebrafish are significantly cheaper and easier to maintain than mice, allowing large numbers to be used for systematic drug screening. The model enables high-throughput pharmacological testing with multiple fish per experiment, dramatically increasing productivity while reducing costs associated with animal housing, care, and experimental throughput
2Productivity
If zebrafish models are used for CCM research, then costs and workload are reduced, but the ability to replicate blood flow-dependent hemorrhagic conditions is lost
Solution Approach 1:
The patent introduces a cardiac-specific promoter to drive CCM protein expression in the heart, creating a parameter change that enables blood flow generation. This modification allows the zebrafish model to develop blood flow-dependent vascular lesions and hemorrhagic conditions in cerebral vessels, accurately replicating human CCM pathology while maintaining high-throughput capabilities
Solution Approach 2:
The model incorporates dynamic blood flow through cardiac-driven circulation, allowing vascular lesions to develop in a blood flow-dependent manner similar to human CCM. This dynamic system enables hemorrhagic conditions to occur naturally in low-flow cerebral vessels, providing pathological accuracy without sacrificing screening efficiency
3Reliability
If complete CCM protein loss is induced in zebrafish, then the CCM phenotype is established, but cardiovascular development defects occur and blood flow is lost
Solution Approach 1:
The patent uses tissue-specific (cardiac/endocardium-specific) expression to restore CCM protein function only in the heart, while leaving other tissues with complete protein loss. This local restoration enables blood flow generation and cardiovascular development without compromising the overall CCM phenotype in cerebral vessels, allowing both phenotype accuracy and blood flow availability
Data Source
Figure 1
Figure 1d~1g
Figure 1continued
AI summary
The invention relates to a transgenic fish lacking at least one endogenous functional protein required for a functional CCM complex, comprising an exogenous nucleic acid encoding a functional version of said at least one protein under the transcriptional control of an endocardium-specific genetic system, wherein said at least one protein required for a functional CCM complex can be selected from the group comprising CCM1 (KRIT1), CCM2, CCM3, and Heg1. In embodiments, the transgenic fish comprises a cardiovascular system with a heart that produces blood flow, and develops vascular lesions in cerebellar blood vessels, in particular in lowly perfused cerebellar blood vessels. The invention also relates to a method for measuring a pharmacological effect of a drug, comprising contacting a transgenic fish according to any one of claims 1 to 10 with a drug, and measuring a pharmacological effect of the drug, wherein the effect of the drug may be an effect on the formation of vascular lesions, the development of cerebellar cavernous malformation and/or the development of stroke. Furthermore, the invention comprises various uses of the transgenic fish of the invention.